Novus Partners with Silicon Valley Technologys PotBotics An App
That Personalizes Cannabis Treatment While Being A Lead Magnet For
Supplemental Insurance Members
MIAMI, FL -- (Marketwired) August 2, 2017 Novus Acquisition and
Development, Corp. (OTC Markets: NDEV), the nations first healthcare
insurance carrier/aggregator in the medical cannabis sector, today
announced the signing of strategic partnership agreement with
PotBotics, a Silicon Valley data aggregation and technology
provider to the medical cannabis market.
Novus MedPlans agreement with PotBotics will utilize its unique
medical marijuana App, that incorporates a recommendation engine
for cannabinoid levels and custom strains to help current and
future Novus MedPlan members make more informed decisions. The
agreement allows a Cost Per Acquisition (CPA), also known as Pay
Per Acquisition (PPA), an online digital marketing pricing model
whereby Novus pays PotBotics for patient acquisition(s).
This innovative App is designed to guide patients on the journey
of selecting the right cannabis for their specific health needs.
The App logs the variable efficacy of the patient relief, progress
tracking and attains useful insights on the patients medication
regimen.
How the App works is through a compiled database of
comprehensive cannabinoid profiles suited to treating 37 patient
ailments and its algorithm uses the largest peer-reviewed science
research to recommend strains in the local area that have the best
chance of relieving a patients symptoms. It then guides the
patients to nearby participating dispensary locations that stock
the recommended types of cannabis or locate a nearby doctor to
obtain state approved medical marijuana card.
Novus chose PotBotics for the following value added
characteristics:
1) Identify and educate patient on
cannabis med options.
2) HIPAA Compliant.
3) The Apps brand identity, as covered
in The New York Times, CNBC, Forbes, Entrepreneur Magazine,
Newsweek Publication, Inc. Magazine and Fortune Magazine.
4) Ease and automation of the patient
user experience based on scientific recommendations.
5) Assist in understanding strain names
down to the ideal cannabinoid percentage.
6) A prudent approach relating to
patient's tolerance towards cannabis and medical condition.
7) Access PotBotics data to assist in
actuarial assessment for more diversified benefit packages.
8) Direct patients to Novus MedPlan
provider network.
Novus Chief Executive Officer, Frank Labrozzi, stated, PotBotics
App will allow Novus to continue its expansion in our digital
advertising assets and utilize the App as a natural lead magnet
that targets active consumer behavioral patterns relating to
cannabis med choices.
PotBotics, Chief Executive Officer, David Goldstein, commented,
Novus MedPlans unique business model to the cannabis industry makes
it the right fit to further monetize our APP and with their
aggressive advertising approach allows both entities gain valued
exposure.
Download the App now, its free
About PotBotics
PotBotics, with offices in Palo Alto, CA and New York, NY, the
Apps mission is to bring clarity for medical cannabis patients.
PotBotics is the leading data aggregation and technology company
focused on the global medical cannabis market. As the first company
to collect data from cultivation to patient consumption, PotBotics
is creating the largest centralized hub for medical cannabis
insights and correlations. PotBotics uses its artificial
intelligence, data mining, and technology assets in order to create
bestin-class technology products and services for cannabis
professionals and consumers. The Company's core management team is
comprised of leaders and innovators across the fields of biotech,
robotics, artificial intelligence and the cannabis market - with
strength and experience in technology development, product
commercialization and early stage corporate development.
For more information, please visit: http://www.potbotics.com
About Novus
Novus Acquisition & Development Corp. (OTC Markets: NDEV), through its subsidiary WCIG
Insurance, provides health insurance and related insurance
solutions within the wellness and medical marijuana industries in
states where legal programs exist. Novus has positioned itself to
gain market share within many lines of insurance business within
and outside of the MMJ sector.
Novus will work as outside developers and will not cultivate,
handle, transport grow, extract, dispense, put up for sale, put on
the market, vend, deliver, supply, circulate, or trade cannabis or
any substances that violate the United States law or the Controlled
Substances Act, nor does it intend to do so in the future and will
continue to follow state and federal laws. The statements made
about specific products have not been evaluated by the United
States Food and Drug Administration (FDA) and are not intended to
diagnose, treat, cure or prevent disease. All information provided
on these press releases or any information contained on or in any
product label or packaging is for informational purposes only and
is not intended as a substitute for advice from your physician or
other health care professional. Once a push notification is
competed the transaction is solely between the state-licensed
dispensary and the registered patient. The information provided in
this press release is general in nature and does not apply to any
specific U.S. state except where noted. Health insurance
regulations differ in each state and all plans proposed or
implemented can be changed or modified according to compliance
issues by Novus management.
The state laws are in conflict with the federal Controlled
Substances Act. The current administration has effectively stated
that it is not an efficient use of resources to direct federal law
enforcement agencies to prosecute those lawfully abiding by state
designated laws, allowing the use and distribution of medical
marijuana. However, there is no guarantee that the current
administration, nor any future administration, will not change this
policy and decide to enforce the federal laws strongly. Any such
change in the federal government's enforcement of current federal
laws could cause significant financial changes to Novus Medical
Group. While we do not intend to harvest, distribute or sell
cannabis or cannabis related products, we may be harmed by a change
in enforcement by federal or state governments.
Forward-Looking Statements
This release includes forward-looking statements, which are
based on certain assumptions and reflects management's current
expectations. These forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Some of
these factors include: general global economic conditions; general
industry and market conditions and growth rates; uncertainty as to
whether our strategies and business plans will yield the expected
benefits; increasing competition; availability and cost of capital;
the ability to identify and develop and achieve commercial success;
the level of expenditures necessary to maintain and improve the
quality of services; changes in the economy; changes in laws and
regulations, includes codes and standards, intellectual property
rights, and tax matters; or other matters not anticipated; our
ability to secure and maintain strategic relationships and
distribution agreements. Novus Medical Group disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact Information
Corporate:
Chairman and CEO
Frank Labrozzi
frank@ndev.biz
855-228-7355
Investors:
Hayden IR
hart@haydenir.com
917-658-7878
